Allied World Assurance (AWH) Announces Agreement for Development and Commercialization of Early-Detection Test for Identification of Ovarian Cancer
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
Aspira Women’s Health Reports Fourth Quarter and Full Year 2020 Financial Results
March 25, 2021 4:20 PM EDTAUSTIN, Texas, March 25, 2021 (GLOBE NEWSWIRE) -- Aspira Womens Health Inc. (Aspira) (Nasdaq: AWH), a bio-analytical based womens health company focused on gynecologic disease, today reported its financial results for the fourth quarter and year ended December 31, 2020.
In a year dominated by the pandemic, we delivered strong stock price appreciation, growth in revenue and test volume, and financial stability. In addition, we strengthened our team and board of directors. We are starting 2021 by announcing an accelerated product launch of OVASight, a new strategic partnership and increases in our sales footprint, stated... More
Aspira Women’s Health, Inc. Announces an Agreement for the Development and Commercialization of an Early-Detection Test for Identification of Ovarian Cancer
March 25, 2021 4:01 PM EDTAUSTIN, Texas, March 25, 2021 (GLOBE NEWSWIRE) -- Aspira Womens Health, Inc. (Nasdaq: AWH), a bioanalytical-based womens health company, today announced it has entered into an agreement with Dana-Farber Cancer Institute (DFCI), Brigham and Womens Hospital, and Medical University Lodz to evaluate their novel microRNA (miRNA) technology in combination with current AWH technologies, for the development of a highly sensitive and specific high-risk early detection test for ovarian cancer. Ovarian cancer accounts for more deaths than any other cancer of the female reproductive system and is the only gender-specific cancer with an over... More
